Vasculitis in Adults Testing Algorithm

Total Page:16

File Type:pdf, Size:1020Kb

Vasculitis in Adults Testing Algorithm Vasculitis in Adults Testing Click here for topics associated with this algorithm Abbreviations INDICATIONS FOR TESTING Unexplained systemic illness with organ involvement including ≥1 of the ANA Anti-Nuclear Antibody following ANCA Anti-Neutrophil Cytoplasmic Antibodies • Upper airway (chronic rhinosinusitis) + Keratitis CRP C-Reactive Protein • Renal (microscopic hematuria or glomerulonephritis) + Vestibuloauditory signs and symptoms MPO Antimyeloperoxidase • Pulmonary (pulmonary infiltrates, dyspnea, cough, hemoptysis) PR3 Antiproteinase 3 • Dermatologic (palpable purpura, urticaria) UA Urinalysis • Neurologic (mononeuritis multiplex) Angiography demonstrates aortitis Must rule out infection, neoplasm, drug effect NOTE: Classification is primarily based on Cogan syndrome predominant vessels involved. Confirms presence of ANA + Connective tissue disease/rheumatic Recurrent oral ulceration plus 2 of the or disease following: HIV + To determine systems involved, or • Genital ulceration or ORDER UA - HIV • Eye lesions Treponema • UA CRP + or • Skin lesions pallidum + • CRP ANCA - • Pathergy test positive Syphilis • Urea nitrogen/creatinine Pulmonary • ANCA symptoms - • ANA HIV - • Syphilis screening Treponema Behçet syndrome UA +/- • HIV testing pallidum - CRP + ORDER • CBC with platelet count and ANA - Biopsy of involved site differential + Blood pressure differential between upper extremities + Hypertension, young female ORDER Positive Negative Biopsy of involved site UA - UA + Angiography demonstrates aneurysmal CRP - CRP + formation, irregular vessel walls, and Secondary Primary disease occlusion in aorta vasculitis without vasculitis Takayasu arteritis ORDER (aortic arch syndrome) Vasculitis demonstrated Biopsy of involved site No vasculitis + Headache demonstrated +/- Jaw claudication Vasculitis likely +/- Vision symptoms associated with other + Painful temporal artery to palpation disease diagnosis +/- Polymyalgia rheumatica Consider other etiologies for > 50 yrs old systemic illness (other infection, autoimmune) Biopsy of temporal artery demonstrates medium and large artery vasculitis ANCA - ANCA + with giant cell formation Giant cell arteritis (Temporal arteritis) +/- Pulmonary signs - Pulmonary signs and and symptoms symptoms No palpable purpura Palpable purpura present ORDER ORDER Skin biopsy of involved area Antimyeloperoxidase Antiproteinase 3 Glomerular Basement predominates (MPO) predominates Membrane Antibody, IgG by (PR3) Multiplex Bead Assay and IFA Demonstrates Demonstrates inflammatory IgA+ infiltrates and immunoglobulin and C3 complement deposition Negative Positive deposition • Pulmonary signs and symptoms, including a Pulmonary and No pulmonary history of asthma upper airway IgA vasculitis ORDER signs/symptoms If strong Renal biopsy required to • Mononeuritis multiplex signs/symptoms (Henoch Schőnlein Cryoglobulin, suspicion confirm antiglomerular • Eosinophilia purpura) Qualitative exists, order basement membrane disease a biopsy (Goodpasture syndrome) ORDER ORDER ORDER Cryoglobulins present Biopsy of involved site Biopsy of involved site Biopsy of involved site Severe widespread Demonstrates crescentic small and medium glomerulonephritis or Vasculitis present on biopsy necrotizing linear IgG deposits in vasculitis Demonstrates Demonstrates the GBM Demonstrates small and medium artery, small artery and No Yes small artery, capillary and venule vein necrotizing capillary and vasculitis, with vasculitis with granulomatous reactions venule vasculitis Polyarteritis nodosa Goodpasture Rule out underlying Cryoglobulinemic granulomas a and eosinophilia (PAN) syndrome diseases such as hepatitis vasculitis B or C, SLE, Sjögren Eosinophilic Granulomatosis Microscopic Negative Positive granulomatosis with with polyangiitis polyangiitis polyangiitis (formerly (formerly Churg-Strauss Wegener aUp to 30% of patients with Goodpasture syndrome Essential Cryoglobulinemia secondary syndrome) granulomatosis) may also be ANCA+ cryoglobulinemia to underlying disease © 2006 ARUP Laboratories. All Rights Reserved. www.arupconsult.com Last updated: September 2021.
Recommended publications
  • Apixaban-Induced Cutaneous Hypersensitivity: a Case Series with Evidence of Cross-Reactivity
    Volume 26 Number 10| October 2020| Dermatology Online Journal || Letter 26(10):20 Apixaban-induced cutaneous hypersensitivity: a case series with evidence of cross-reactivity Nasro A Isaq1 BS, Whitney M Vinson2 MD, Sahand Rahnama-Moghadam2 MD MS Affiliations: 1Indiana University School of Medicine, Indianapolis, Indiana, USA, 2Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, USA Corresponding Author: Sahand Rahnama-Moghadan MD MS, Department of Dermatology, Indiana University School of Medicine, 545 Barnhill Drive, Emerson Hall 139, Indianapolis, IN 46202, Tel: 317-944-7744, Email: [email protected] Keywords: novel oral anticoagulants (NOACs), apixaban, 2 weeks she developed low-grade fevers, chills, rivaroxaban, drug induced rash, apixaban hypersensitivity nausea, shortness of breath, headaches, and cough. reaction, rivaroxaban cross reactivity, novel oral She was admitted to the hospital where computed anticoagulant induced hypersensitivity reaction, apixaban tomography of the chest demonstrated ground glass induced rash opacities located peripherally within her lungs. Laboratory results showed a decrease in hemoglobin, elevated dsDNA, positive rheumatoid To the Editor: factor, and elevated beta-2 glycoprotein concerning Atrial fibrillation is the most common cardiac arrhythmia affecting more than 2.7 million patients for drug-induced lupus. Her apixaban was held owing to concern for hemorrhage. A in the US [1]. As the population ages, it is predicted bronchoalveolar lavage was performed revealing to affect more than 6-12 million people by 2050 [1]. eosinophilic predominance, suggestive of Patients with atrial fibrillation are at increased risk for eosinophilic pneumonia secondary to a connective thromboembolic events and require anticoagulation therapy to prevent thrombus formation and stroke. tissue disease versus drug reaction.
    [Show full text]
  • Goodpasture Syndrome
    orphananesthesia Anaesthesia recommendations for Goodpasture syndrome Disease name: Goodpasture syndrome ICD 10: M31.0 Synonyms: Goodpasture’s syndrome (GS), anti-glomerular basement membrane disease, crescentic glomerulonephritis type 1, GPS Disease summary: Goodpasture syndrome is a rare and organ-specific autoimmune disease (Gell and Coombs classification type II). It is mediated by anti-glomerular basement membrane (anti-GBM) antibodies [7]. The disease was first described by Dr. Ernest Goodpasture in 1919 [6], whereby the glomerular basement membrane was first identified as antigen in 1950s. More than one decade later, researchers succeeded in defining the association between antibodies taken from diseased kidneys and nephritis [7]. The disorder is characterised by autoantibodies targeting at the NC1-domain of the α3 chain of type IV collagen in the glomerular and alveolar basement membrane with activation of the complement cascade among other things [7,17]. The exclusive location of this α3 subunit in basement membranes only in lung and kidney is responsible for the unique affection of these two organs in GPS [7]. Nevertheless, the aetiology and the triggering stimuli for anti-GBM production remain unknown. Due to the fact that patients with specific human leukocyte antigen (HLA) types are more susceptible, a genetic predisposition HLA-associated seems possible [4,7]. However, because this strongly associated allele is frequently present, there seem to be additional behavioural or environmental factors influencing immune response and disease expression. The latter may include respiratory infections (e.g., influenza A2), exposition to hydrocarbon fumes, organic solvents, metallic dust, tobacco smoke, certain drugs (i.e., rifampicin, allopurinol, cocaine), physical damage to basement membrane (e.g., lithotripsy or membranous glomerulonephritis) as well as lymphocyte-depletion therapy (such as alemtuzumab), but unequivocal evidence is lacking [4,7,9,17].
    [Show full text]
  • Goodpasture's Syndrome: an Analysis of 29 Cases
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 13 (1978), pp. 492—504 Goodpasture's syndrome: An analysis of 29 cases CLINTON A. TEAGUE, PETER B. DOAK, IAN J. SIMPSON, STEPHEN P. RAINER, and PETER B. HERDSON The Departments of Pathology and Medicine, University of Auckland School of Medicine, Auckland, New Zealand Goodpasture's syndrome: An analysis of 29 cases. The patho- ation between lung hemorrhage and glomeruloneph- logic features of 29 cases of Goodpasture's syndrome occurring during a 13-yr period in Auckland have been reviewed and corre- ntis classically affecting young men. They referred to lated with clinical findings. There were 20 males and nine females such a patient reported about 40 years previously by in the series; two of the males and three of the females were Goodpasture [2]. During the past two decades, a Maoris. Age at the time of onset of symptoms ranged from 17 to 75 great deal has been learned about the immunological yr, with about 76% of the patients being from 17 to 27 yr of age. Sixteen (55%) of the patients died from less than a week up to aspects of several forms of glomerulonephritis, in- about two years following the onset of symptoms, and the remain- cluding the anti-glomerular basement membrane ing 13 are alive from 30 weeks to 14 yr after initial presentation. (anti-GBM) type of disease with cross-reactivity be- Underlying renal disease varied from mild focal glomerulitis to end-stage glomerulonephritis by light microscopy, but characteris- tween lung and kidney which is a feature of Good- tic glomerular changes were seen in all specimens examined by pasture's syndrome [3].
    [Show full text]
  • ANCA--Associated Small-Vessel Vasculitis
    ANCA–Associated Small-Vessel Vasculitis ISHAK A. MANSI, M.D., PH.D., ADRIANA OPRAN, M.D., and FRED ROSNER, M.D. Mount Sinai Services at Queens Hospital Center, Jamaica, New York and the Mount Sinai School of Medicine, New York, New York Antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis is the most common primary sys- temic small-vessel vasculitis to occur in adults. Although the etiology is not always known, the inci- dence of vasculitis is increasing, and the diagnosis and management of patients may be challenging because of its relative infrequency, changing nomenclature, and variability of clinical expression. Advances in clinical management have been achieved during the past few years, and many ongoing studies are pending. Vasculitis may affect the large, medium, or small blood vessels. Small-vessel vas- culitis may be further classified as ANCA-associated or non-ANCA–associated vasculitis. ANCA–asso- ciated small-vessel vasculitis includes microscopic polyangiitis, Wegener’s granulomatosis, Churg- Strauss syndrome, and drug-induced vasculitis. Better definition criteria and advancement in the technologies make these diagnoses increasingly common. Features that may aid in defining the spe- cific type of vasculitic disorder include the type of organ involvement, presence and type of ANCA (myeloperoxidase–ANCA or proteinase 3–ANCA), presence of serum cryoglobulins, and the presence of evidence for granulomatous inflammation. Family physicians should be familiar with this group of vasculitic disorders to reach a prompt diagnosis and initiate treatment to prevent end-organ dam- age. Treatment usually includes corticosteroid and immunosuppressive therapy. (Am Fam Physician 2002;65:1615-20. Copyright© 2002 American Academy of Family Physicians.) asculitis is a process caused These antibodies can be detected with indi- by inflammation of blood rect immunofluorescence microscopy.
    [Show full text]
  • A Review of Primary Vasculitis Mimickers Based on the Chapel Hill Consensus Classification
    Hindawi International Journal of Rheumatology Volume 2020, Article ID 8392542, 11 pages https://doi.org/10.1155/2020/8392542 Review Article A Review of Primary Vasculitis Mimickers Based on the Chapel Hill Consensus Classification Farah Zarka ,1 Charles Veillette ,1 and Jean-Paul Makhzoum 2 1Hôpital du Sacré-Cœur de Montreal, University of Montreal, Canada 2Vasculitis Clinic, Department of Internal Medicine, Hôpital du Sacré-Coeur de Montreal, University of Montreal, Canada Correspondence should be addressed to Jean-Paul Makhzoum; [email protected] Received 10 July 2019; Accepted 7 January 2020; Published 18 February 2020 Academic Editor: Charles J. Malemud Copyright © 2020 Farah Zarka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Primary systemic vasculitides are rare diseases that may manifest similarly to more commonly encountered conditions. Depending on the size of the vessel affected (large vessel, medium vessel, or small vessel), different vasculitis mimics must be considered. Establishing the right diagnosis of a vasculitis mimic will prevent unnecessary immunosuppressive therapy. 1. Introduction 2. Large-Vessel Vasculitis Mimics Vasculitides are rare heterogenous diseases that affect vessel Large-vessel vasculitis (LVV) is an inflammatory vascu- walls as the main site of inflammation. Organs affected vary lopathy affecting large arteries; giant cell arteritis (GCA) depending on the type and size of blood vessels involved and Takayasu’s arteritis (TAK) are the two main docu- [1]. Autoimmune vasculitis can be primary (idiopathic) or mented variants, each with their own characteristic fea- secondary to an underlying disease.
    [Show full text]
  • Immune-Pathophysiology and -Therapy of Childhood Purpura
    Egypt J Pediatr Allergy Immunol 2009;7(1):3-13. Review article Immune-pathophysiology and -therapy of childhood purpura Safinaz A Elhabashy Professor of Pediatrics, Ain Shams University, Cairo Childhood purpura - Overview vasculitic disorders present with palpable Purpura (from the Latin, purpura, meaning purpura2. Purpura may be secondary to "purple") is the appearance of red or purple thrombocytopenia, platelet dysfunction, discolorations on the skin that do not blanch on coagulation factor deficiency or vascular defect as applying pressure. They are caused by bleeding shown in table 1. underneath the skin. Purpura measure 0.3-1cm, A thorough history (Table 2) and a careful while petechiae measure less than 3mm and physical examination (Table 3) are critical first ecchymoses greater than 1cm1. The integrity of steps in the evaluation of children with purpura3. the vascular system depends on three interacting When the history and physical examination elements: platelets, plasma coagulation factors suggest the presence of a bleeding disorder, and blood vessels. All three elements are required laboratory screening studies may include a for proper hemostasis, but the pattern of bleeding complete blood count, peripheral blood smear, depends to some extent on the specific defect. In prothrombin time (PT) and activated partial general, platelet disorders manifest petechiae, thromboplastin time (aPTT). With few exceptions, mucosal bleeding (wet purpura) or, rarely, central these studies should identify most hemostatic nervous system bleeding;
    [Show full text]
  • Anti-Glomerular Basement Membrane (GBM) Disease (Goodpasture's Syndrome)
    Patient information – Goodpasture’s Syndrome Anti-Glomerular Basement Membrane (GBM) Disease (Goodpasture’s Syndrome) What is it? Goodpasture’s Syndrome is a type of vasculitis (inflammation of blood vessels), which affects the kidneys and the lungs. What causes it? The body normally produces antibodies to fight off infection and disease. In this case, your body makes an antibody that can attack and damages a membrane in your kidneys and lungs. What symptoms might I have? You may feel short of breath and cough up blood. The kidney damage may cause blood-stained or frothy urine or actual kidney failure. Is it serious? Without treatment, the condition can be life-threatening. In some cases, it may be too advanced for treatment to save the kidneys and dialysis will be necessary. However, powerful treatment is now very successful in saving lives and kidney function. Inpatient treatment As soon as diagnosis is made (on blood test or kidney biopsy), treatment will start with Prednisolone (steroid) and Cyclophosphamide (immunosuppressant). · Prednisolone 1mg/Kg of body weight (max 60mg) · IV Cyclophosphamide · Plasma exchange daily for 14 days or until antibody negative Discharge medication [Week One] Prednisolone Inpatient dose Lansoprazole 30mg daily Alendronate (non-dialysis) 70mg weekly Nystatin 1ml four times a day Septrin 480mg daily Anti-GBM Disease (Goodpasture’s Syndrome), March 2019 1 Anti-GBM Disease (Goodpasture’s Syndrome) Outpatient treatment The condition is dangerous, requiring powerful treatment that can have serious side effects. You will be seen often and monitored carefully. Your blood will be checked for its white cell count (WCC) to check how it would respond to infection.
    [Show full text]
  • Vasculitis: Pearls for Early Diagnosis and Treatment of Giant Cell Arteritis
    Vasculitis: Pearls for early diagnosis and treatment of Giant Cell Arteritis Mary Beth Humphrey, MD, PhD Professor of Medicine McEldowney Chair of Immunology [email protected] Office Phone: 405 271-8001 ext 35290 October 2019 Relevant Disclosure and Resolution Under Accreditation Council for Continuing Medical Education guidelines disclosure must be made regarding relevant financial relationships with commercial interests within the last 12 months. Mary Beth Humphrey I have no relevant financial relationships or affiliations with commercial interests to disclose. Experimental or Off-Label Drug/Therapy/Device Disclosure I will be discussing experimental or off-label drugs, therapies and/or devices that have not been approved by the FDA. Objectives • To recognize early signs of vasculitis. • To discuss Tocilizumab (IL-6 inhibitor) as a new treatment option for temporal arteritis. • To recognize complications of vasculitis and therapies. Professional Practice Gap Gap 1: Application of imaging recommendations in large vessel vasculitis Gap 2: Application of tocilizimab in treatment of giant cell vasculitis Cranial Symptoms Aortic Vision loss Aneurysm GCA Arm PMR Claudication FUO Which is not a risk factor or temporal arteritis? A. Smoking B. Female sex C. Diabetes D. Northern European ancestry E. Age Which is not a risk factor or temporal arteritis? A. Smoking B. Female sex C. Diabetes D. Northern European ancestry E. Age Giant Cell Arteritis • Most common form of systemic vasculitis in adults – Incidence: ~ 1/5,000 persons > 50 yrs/year – Lifetime risk: 1.0% (F) 0.5% (M) • Cause: unknown At risk: Women (80%) > men (20%) Northern European ancestry>>>AA>Hispanics Age: average age at onset ~73 years Smoking: 6x increased risk Kermani TA, et al Ann Rheum Dis.
    [Show full text]
  • DIFFERENTIAL DIAGNOSIS of Hypersensitivity Vasculitis
    HIGHLIGHTS FROM MEDICAL GRAND ROUNDS renal disease also is rare. However, certain types of kidney posure to an exogenous antigen such as a drug, serum, disease are associated with a higher incidence of hyper- toxin, or to an infection. Typically, the onset of vasculitis uricemia and gout, including chronic lead nephropathy, occurs 7 to 10 days after exposure to the antigen. The polycystic disease, amyloidosis, analgesic nephropathy, characteristic rash presents as palpable purpura, although and medullary cystic disease. Hypertension and its ulcers, nodules, bullae, or urticaria also may develop in therapy are associated with an increased incidence of some patients. hyperuricemia and gout. On biopsy, the lesions display polymorphonuclear The management of concurrent marked hyper- leukocytes and associated leukocytoclasis, but the in- uricemia and chronic renal disease is directed to preser- filtrates may be predominantly mononuclear. Im- vation of renal function, blood pressure control, and munofluorescent studies often show deposition of com- reduction of the serum uric acid. Uric acid homeostasis plement and immunoglobulins in vessel walls, and other can be achieved by maintaining urine flow (>2 L/d), techniques may show soluble immune complexes and restricting dietary purines and excessive alcohol, and, if evidence of complement activation; however, these needed, allopurinol in the lowest dose that can main- laboratory findings are neither universal nor necessary for tain a near-normal serum uric acid. Therapy should the diagnosis. start with 50 mg/d and increase in 50-mg increments The clinical course is usually self-limited. Varying until the level is under control. Generally, the dosage is degrees of fever, malaise, and weight loss may occur and 100 mg/d for every 30 cc/min of GFR.
    [Show full text]
  • Pattern of Arterial Involvement Ofthe
    368 BritishJournal ofOphthalmology, 1991, 75, 368-371 CASE REPORTS Br J Ophthalmol: first published as 10.1136/bjo.75.6.368 on 1 June 1991. Downloaded from Pattern of arterial involvement of the head, neck, and eyes in giant cell arteritis: three case reports Z Butt, J F Cullen, E Mutlukan Abstract arteries at necropsy showed characteristic The findings oftwo post-mortem examinations changes ofGCA (see below). and one CT scan ofpatients with biopsy proved Post-mortenfindings. Macroscopically the main giant cell arteritis (GCA) are presented. The arteries at the base ofthe brain were virtually free presence or absence of intracranial involve- from atheroma, but a plug ofrather firm clot was ment in GCA is discussed. present in the stump ofthe right internal carotid. The circle of Willis was normally constituted. Several haemorrhagic infarcts were noted in the Giant cell arteritis (GCA) is rarely fatal, and cerebrum (frontal, parietal, temporal, and references to the condition in post-mortem occipital lobes) and cerebellum. Microscopic material are uncommon.'-16 However, this may examination confirmed that these were be related to non-recognition of a fatal outcome very recent, practically terminal, infarcts. in patients with GCA and because post-mortem Occasionally small meningeal arteries overlying examinations of elderly patients dying from the cortical infarcts were noted to contain recent vascular disorders are not routinely carried out. thrombus, but in none of the sections was there GCA may be concealed among the cases diag- evidence ofgiant cell arteritis. nosed as ischaemic catastrophes due to arterio- Sections of the temporal, ophthalmic, verte- sclerosis. " bral, internal carotid (in neck), external carotid, Patients suffering from GCA have a range of left common carotid, and coronary arteries symptoms including headache, jaw claudication, showed changes typical of giant cell arteritis.
    [Show full text]
  • Jordan M. Garrison, Md Facs Fasmbs What Are We Talking About?
    PERIPHERAL VASCULAR DISEASE JORDAN M. GARRISON, MD FACS FASMBS WHAT ARE WE TALKING ABOUT? Peripheral Arterial Disease (PAD) • Near or Complete obstruction of > 1 Peripheral Artery Peripheral Venous Reflux Disease • Varicose Veins • Chronic Venous Stasis Ulcer Disease • Phlegmasia Cerulia Dolans or Alba Dolans (Milk Leg) • Deep Vein Thrombosis and Pulmonary Embolus Disease Coronary Artery Disease ◦ Myocardial Infarct Aneurysmal Disease • Aortic • Popliteal Cerebral and Carotid Artery Disease • Stroke • TIA Renal Vascular Hypertensive Disease • High Blood Pressure • Kidney Failure Peripheral Arterial Disease PREVELANCE Males > Females 10% of People over 60 Race • AA double the rate of all other ethnicities High Income Countries Peripheral Arterial Disease RISK FACTORS Smoking is the #1 risk factor Diabetes Mellitus Diet Obesity ETOH Cholesterol Heredity Lifestyle Homocysteine, C Reactive Protein, Fibrinogen Arterial Anatomy Lower Extremity Anatomy Plaque Formation Plaque Peripheral Arterial Disease Claudication • Disabling • Intestinal Limb Threatening Ischemia(LTI) Critical Limb Ischemia(CLI) • Rest Pain • Tissue Loss • Gangrene Disabling Claudication Intestinal Ischemia Intestinal Claudication Peripheral Arterial Disease Claudication • Disabling • Intestinal Limb Threatening Ischemia(LTI) Critical Limb Ischemia(CLI) • Rest Pain • Tissue Loss • Gangrene Rest Pain/ Dependent Rubor Tissue Loss Gangrene Peripheral Artery Disease Diagnosis Segmental Pressures • Lower extremity Blood Pressures ABI • Nl >1.0, Diabetes will give elevated reading
    [Show full text]
  • Giant Cell Arteritis Misdiagnosed As Temporomandibular Disorder: a Case Report and Review of the Literature
    360_Reiter.qxp 10/14/09 3:17 PM Page 360 Giant Cell Arteritis Misdiagnosed as Temporomandibular Disorder: A Case Report and Review of the Literature Shoshana Reiter, DMD Giant cell arteritis (GCA) is a systemic vasculitis involving medium Teacher and large-sized arteries, most commonly the extracranial branches Department of Oral Rehabilitation of the carotid artery. Early diagnosis and treatment are essential to avoid severe complications. This article reports on a GCA case Ephraim Winocur, DMD and discusses how the orofacial manifestations of GCA can lead to Lecturer misdiagnosis of GCA as temporomandibular disorder. GCA Department of Oral Rehabilitation should be included in the differential diagnosis of orofacial pain in Carole Goldsmith, DMD the elderly based on the knowledge of related signs and symptoms, Instructor mainly jaw claudication, hard end-feel limitation of range of Department of Oral Rehabilitation motion, and temporal headache. J OROFAC PAIN 2009;23:360–365 Alona Emodi-Perlman, DMD Key words: Giant cell arteritis, jaw claudication, Teacher temporomandibular disorders, trismus Department of Oral Rehabilitation Meir Gorsky, DMD Professor Department of Oral Pathology and Oral iant cell arteritis (GCA) is a systemic vasculitis involving Medicine the large and medium-sized vessels, particularly the extracranial branches of the carotid artery. It is more com- The Maurice and Gabriela Goldschleger G School of Dental Medicine mon in women (M:F ratio 2:5) and usually affects patients older 1 Tel Aviv University, Israel than 50 years with an increased risk with age. The highest preva- lence of GCA has been reported in Scandinavian populations and Correspondence to: in those with a strong Scandinavian ethnic background.2 Dr.
    [Show full text]